Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis

OBJECTIVE: To assess safety outcomes for the induction therapies alemtuzumab and autologous hematopoietic stem cell transplantation (AHSCT) compared to noninduction disease-modifying therapies. METHODS: We performed a population-based cohort study linking the Swedish Multiple Sclerosis Register to n...

Descripción completa

Detalles Bibliográficos
Autores principales: Alping, Peter, Burman, Joachim, Lycke, Jan, Frisell, Thomas, Piehl, Fredrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032381/
https://www.ncbi.nlm.nih.gov/pubmed/33514645
http://dx.doi.org/10.1212/WNL.0000000000011545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032381/
https://www.ncbi.nlm.nih.gov/pubmed/33514645
http://dx.doi.org/10.1212/WNL.0000000000011545

Ejemplares similares